Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
about
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@ast
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@en
type
label
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@ast
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@en
prefLabel
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@ast
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@en
P2093
P2860
P1476
Nilotinib versus dasatinib as ...... ysis based on real-world data.
@en
P2093
George Joseph
Liangyi Fan
Subrata Bhattacharyya
Todor Totev
P2860
P304
P356
10.1080/13696998.2016.1261032
P407
P50
P577
2016-11-14T00:00:00Z